Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer.

ABSTRACT:

Background

Prognostication has been used to identify patient populations that could potentially benefit from treatment de-escalation. In patients with hormone receptor-positive (HRpos), human epidermal growth factor receptor 2-negative (HER2neg) early breast cancer (eBC), treatment de-escalation classically involved omitting chemotherapy. With recently developed specialized therapies that require hands-on side-effect management, the therapeutic landscape is changing and therapy decisions are no longer based only on prognosis, but also consider potential side-effects. Therefore, identification of patient groups based on prognostication has gained importance.

Materials and methods

In this retrospective analysis, a population of 2359 node-negative HRpos/HER2neg eBC patients was

SUBMITTER: Seitz K 

PROVIDER: S-EPMC11558624 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature